OUR
VISION
Biologics, like monoclonal antibodies and viral vectors, make up rapidly growing classes of drugs. They are also critical research tools and essential for the development of many new diagnostics.
While chromatography has been a mainstay of small molecules, these larger, bulky biologics require a new approach to downstream manufacturing. Isolere Bio was founded with the vision of simplifying and streamlining the purification of biotherapeutics to improve global access to these important drugs.
We are currently focused on developing this technology for the manufacturing of antibodies and adeno-associated virus (AAV). We are working to develop a low-cost, high throughput, and scalable purification platform and are actively seeking research collaborators in development and validation.
LOW COST
Our product is made entirely recombinantly in E. coli and has no synthetic scaffold. This eliminates the cost of the solid support and chemical conjugation.
SCALABLE
Our process scales linearly, providing a seamless transition from bench to industry scale production.
EASE OF USE
Our technology requires a simple tangential flow filtration (TFF) setup rather than complex chromatography equipment.
MULTIPLE FORMATS
From high throughput 96-well plates, to all-in-one kits, to bulk reagent, our technology can be tailored to suit your needs.
SPEED
Complete an entire round of purification with TFF in under 30 minutes! High flux will eliminate the capture step bottleneck and permeate control enables seamless development of a continuous downstream processes.
CAPACITY
Our reagent binds and elutes the target in solution, eliminating the mass transfer constraints of traditional packed bed chromatography
